TransMedics Group, Inc. (TMDX)
Market Cap | 4.36B |
Revenue (ttm) | 296.92M |
Net Income (ttm) | -10.20M |
Shares Out | 32.94M |
EPS (ttm) | -0.34 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 1,169,263 |
Open | 132.24 |
Previous Close | 132.04 |
Day's Range | 128.29 - 137.22 |
52-Week Range | 36.42 - 137.22 |
Beta | 1.87 |
Analysts | Buy |
Price Target | 104.71 (-20.94%) |
Earnings Date | Apr 30, 2024 |
About TMDX
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung trans... [Read more]
Financial Performance
In 2023, TMDX's revenue was $241.62 million, an increase of 158.53% compared to the previous year's $93.46 million. Losses were -$25.03 million, -30.92% less than in 2022.
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for TMDX stock is "Buy." The 12-month stock price forecast is $104.71, which is a decrease of -20.94% from the latest price.
News
TransMedics Reports First Quarter 2024 Financial Results
ANDOVER, Mass. , April 30, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end...
TransMedics to Report First Quarter 2024 Financial Results on April 30, 2024
ANDOVER, Mass. , April 16, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end...
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANDOVER, Mass. , April 8, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-...
TMDX INVESTOR NOTICE: ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages TransMedics Group, Inc. Investors to Inquire About Securities Class Action Investigation - TMDX
NEW YORK , March 2, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of TransMedics Grou...
TransMedics to Present at Upcoming March Investor Conferences
ANDOVER, Mass. , Feb. 28, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-...
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages TransMedics Group, Inc. Investors to Inquire About Securities Class Action Investigation – TMDX
NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of TransMedics Group, Inc. (NASDA...
TransMedics Reports Fourth Quarter and Full Year 2023 Financial Results
ANDOVER, Mass. , Feb. 26, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-...
TransMedics to Report Fourth Quarter and Full Year 2023 Financial Results on February 26, 2024
ANDOVER, Mass. , Feb. 12, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-...
TransMedics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
ANDOVER, Mass. , Dec. 18, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-...
TransMedics to Present at the Piper Sandler 35th Annual Healthcare Conference
ANDOVER, Mass. , Nov. 14, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-...
TransMedics' stock pops after organ-transplant company's ‘blockbuster' third-quarter results
TransMedics Group Inc. shares TMDX, -5.70% jumped more than 40% premarket on Tuesday after the company reported third-quarter results reflecting growing demand for its organ-transplant services and ra...
TransMedics Reports Third Quarter 2023 Financial Results
ANDOVER, Mass. , Nov. 6, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-s...
TransMedics to Report Third Quarter 2023 Financial Results on November 6, 2023
ANDOVER, Mass. , Oct. 23, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-...
TransMedics to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
ANDOVER, Mass. , Aug. 28, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-...
TransMedics Completes Acquisition of Summit Aviation
ANDOVER, Mass. , Aug. 16, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-...
TransMedics Reports Second Quarter 2023 Financial Results
ANDOVER, Mass. , Aug. 3, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-s...
Bridge to Life Divests Certain Assets to TransMedics
NORTHBROOK, Ill. , Aug. 2, 2023 /PRNewswire/ -- Bridge to Life Ltd.
TransMedics Acquires Warm Perfusion EVOSS™ and Cold Perfusion LifeCradle® Technologies from Bridge to Life
ANDOVER, Mass. , Aug. 2, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-s...
TransMedics Signs Definitive Agreement to Acquire Summit Aviation to Expand TransMedics Aviation Capabilities for Organ Transplantation
Establishes the first national provider of air logistics dedicated to organ transplantation in the U.S. ANDOVER, Mass. , Aug. 1, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: T...
TransMedics Appoints Anil Ranganath as Senior Vice President, General Counsel and Corporate Secretary
ANDOVER, Mass. , July 26, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-...
TransMedics to Present at the Canaccord Genuity 43rd Annual Growth Conference
ANDOVER, Mass. , July 26, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-...
TransMedics to Report Second Quarter 2023 Financial Results on August 3, 2023
ANDOVER, Mass. , July 20, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-...
TransMedics Group, Inc. Prices $400 Million of Convertible Senior Notes Due 2028
ANDOVER, Mass. , May 8, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-st...
TransMedics Group, Inc. Announces Proposed Offering of $300 Million of Convertible Senior Notes Due 2028
ANDOVER, Mass. , May 8, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-st...
TransMedics Reports First Quarter 2023 Financial Results
ANDOVER, Mass. , May 1, 2023 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-st...